We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Cardiology

Low-Dose Rivaroxaban Fails to Significantly Reduce Left Ventricular Thrombosis in Anterior STEMI: Results of the APERITIF Trial

MedXY Editorial Team•Mar 2, 2026•Cardiology
anticoagulationCardiac Magnetic ResonanceRivaroxaban

Highlight

The APERITIF trial evaluated the efficacy of adding very low-dose rivaroxaban (2.5 mg twice daily) to dual antiplatelet therapy (DAPT) for the prevention of left ventricular (LV) thrombus in patients following anterior ST-segment elevation myocardial infarction (STEMI).

Primary results showed that LV thrombus occurred in 13.7% of the rivaroxaban group compared to 16.6% in the DAPT-only group, a difference that was not statistically significant (P = .34).

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Refining Right Ventricular Assessment in Pulmonary Hypertension: Impact of Postprocessing Techniques on Cardiac MRI MetricsThis study examines how cardiac MRI postprocessing methods, including trabeculation exclusion and pulmonary artery flow measurement sites, significantly influence right ventricular volume and function assessment in pulmonary hypertension paSep 17, 2026Ischaemic Stroke Risk in Atrial Flutter Versus Atrial Fibrillation: Insights from a Finnish Nationwide Registry StudyThis Finnish nationwide study demonstrates that patients with atrial flutter have a substantially lower risk of ischaemic stroke compared to those with atrial fibrillation, highlighting important differences in thromboembolic risk profilesSep 9, 2026Short-Term Anticoagulant Therapy and Subclinical Leaflet Thickening in Transcatheter Aortic Valves: Evidence and Insights from the NOTION-4 TrialThe NOTION-4 trial demonstrates that 3 months of DOAC therapy post-TAVR reduces early HALT incidence compared to SAPT, but benefits diminish after discontinuation, highlighting nuanced balance between thrombosis prevention and bleeding riskSep 1, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Myocardial Fibrosis and Reverse Remodeling After Valve Replacement in Chronic Aortic Regurgitation: Advances and Clinical ImplicationsThis review synthesizes current evidence on myocardial fibrosis and ventricular remodeling after AVR in chronic AR, highlighting imaging biomarkers, remodeling patterns, and functional outcomes relevant to clinical practice.Aug 28, 2026
Navigating Uncertainty: Rapid Evidence Generation and Translation of Anticoagulation Strategies in Noncritically Ill COVID-19 PatientsThis article reviews the accelerated evidence generation for anticoagulation in noncritically ill COVID-19 patients, highlighting how coordinated trials and data sharing influenced clinical guidelines and patient outcomes during the pandemiJul 30, 2026
Recurrent Venous Thromboembolism After Isolated Distal DVT: Insights from the RIDTS TrialThis article reviews the incidence and predictors of recurrent VTE following anticoagulation for isolated distal deep vein thrombosis, highlighting key risk factors and implications for treatment duration and patient management.Jul 7, 2026